Physician profile
Robert G Fleming
NPI 1497844245
$4,150.73
in general payments reported to CMS, 2019-2025
30 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $581 · 2021: $1,037 · 2022: $962 · 2023: $605 · 2024: $154 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $748.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $594.82 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $490.85 | 2019-2023 | Xarelto |
| Amgen INC. | $376.84 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $234.55 | 2021-2024 | Verquvo |
| Pfizer INC. | $198.40 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $192.16 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.69 | 2020-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $165.86 | 2019-2022 | |
| Abbott Laboratories | $141.73 | 2019-2025 | Confirm Rx, Aveir |
| Arbor Pharmaceuticals, INC. | $117.72 | 2021 | |
| Amarin Pharma, INC. | $101.69 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $84.63 | 2022-2024 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.83 | 2019-2023 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $50.77 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.72 | 2019-2022 | |
| Boston Scientific Corporation | $50.06 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $46.56 | 2022 | |
| Novo Nordisk INC | $31.55 | 2022-2023 | Ozempic |
| Scpharmaceuticals INC. | $30.84 | 2023 | |
| Astellas Pharma US INC | $28.99 | 2019 | |
| Cvrx, INC. | $28.69 | 2022 | |
| Medtronic, INC. | $21.11 | 2023 | Onyx Frontier |
| Chiesi USA, INC. | $20.95 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.56 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.63 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $16.13 | 2020 | |
| Ge Healthcare | $14.71 | 2019 | |
| Gilead Sciences, INC. | $13.13 | 2019 | |
| Esperion Therapeutics, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.